AstraZeneca durvalumab receives CDSCO approval for treatment of biliary tract cancer

AstraZeneca durvalumab receives CDSCO approval for treatment of biliary tract cancer

By, Admin 20 February 2023

AstraZeneca India, a leading science-led biopharmaceutical company has announced additional indication approval from Central Drugs Standard Control Organization (CDSCO) for durvalumab to treat biliary tract cancer (BTC) in India. BTC is a group of rare and aggressive gastrointestinal (GI) cancers that form in the cells of the bile ducts (cholangiocarcinoma), gallbladder or ampulla of Vater (where the bile duct and pancreatic duct connect to the small intestine). Apart from ampullary cancer, early-stage BTC often presents without clear symptoms and most new cases of BTC are therefore diagnosed at an advanced stage, when treatment options are limited, and the prognosis is poor. More than 30,000 new cases of BTCs are seen in India every year with 90 per cent of them diagnosed in the advanced stage. In fact, statistics show a high incidence of gallbladder cancer in the northern part of India.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!